38 results about "Aneurysm dissecting" patented technology

The invention discloses an application of a reagent for promoting MARCH2 gene expression in preparation of a medicine for treating aortic aneurysm / dissection, and provides a novel medical application of the MARCH2 gene, the disease progress of the aortic aneurysm / dissection can be slowed down and the prognosis of a patient can be improved by exogenous administration of MARCH2; the invention also provides a reagent for detecting MARCH2 gene expression in preparation of a reagent or a kit for detecting aortic aneurysm / dissection, and also provides a pharmaceutical composition for treating aortic aneurysm / dissection, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an effective amount of active ingredients, and the active ingredients comprise the reagent for promoting MARCH2 gene expression. The invention reveals that MARCH2 can improve aortic aneurysm / dissection vascular injury for the first time, provides a new drug action target for diagnosis and treatment of aortic aneurysm / dissection, and has important clinical value.

The present invention proposes a multi-branch stent for aortic dissection distal aneurysm zoning, belonging to the field of medical device technology. It includes a main covered stent, which is composed of a covering and a main stent. The main covered stent is sequentially arranged from one end to the other end as an upper half, a waist transition section and a lower half; the upper and lower parts of the upper half in the vertical direction are respectively a soft zone and a hard zone; the upper and lower parts of the lower half in the vertical direction are respectively a hard zone and a soft zone; the upper and lower parts are respectively provided with two embedded branch stents; the embedded branch stent in the upper half is used to reconstruct the celiac trunk and the superior mesenteric artery, and the embedded branch stent in the lower half is used to reconstruct the bilateral renal arteries. The present invention increases the adaptability of the anchoring areas at both ends of the main covered stent to the blood vessels, prevents the rupture of the inner membrane sheet of the distal rupture, improves the adhesion of the main covered stent to the tube wall, reduces the incidence of type I internal leakage, reduces the incidence of new stent-induced ruptures after surgery, and can reconstruct visceral arteries at the same time.

Methods, systems, and apparatus, including computer programs encoded on computer storage media, for modeling and risk assessments of abdominal aortic aneurysms. A computing system generates from a set of medical images a three-dimensional (3D) model of the aneurysm, the 3D model defining an outer wall of the aneurysm, an intraluminal thrombus (ILT) region of the aneurysm, and a luminal region of the aneurysm. The system can analyze the 3D model to determine respective values for at least one morphological feature of the aneurysm and at least one biomechanical feature of the aneurysm. Using the respective values for the at least one morphological feature of the aneurysm and the at least one biomechanical feature of the aneurysm, the system can generate a prediction of one or more outcomes related to the aneurysm.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The invention belongs to the technical field of biology, and particularly relates to a tremella aurantialba methanol extract and a preparation method and application thereof.The preparation method comprises the following steps that S1, pretreatment is conducted, specifically, a prepared tremella aurantialba raw material is freeze-dried, and the dried raw material is ground; s2, extraction: adding an extraction solvent methanol-water solution, and performing magnetic stirring for extraction; s3, post-treatment: after the extraction is completed, combining the extracting solutions, filtering, performing vacuum concentration to obtain paste, and performing vacuum freeze-drying on the obtained paste to obtain the tremella aurantialba methanol extract. The tremella aurantialba methanol extract can obviously relieve the occurrence and progress of Ang II induced aneurysm, not only provides a new medicine for preventing and treating abdominal aortic aneurysm, but also provides a new thought for development and utilization of tremella aurantialba resources.

The invention discloses gamma-aminobutyric acid and application of a pharmaceutical composition thereof in preparation of drugs for preventing or treating aortic dissection and aortic aneurysm. The invention provides the application of gamma-aminobutyric acid in preparation of drugs for preventing or treating aortic dissection for the first time, and verifies the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting endothelial cell dysfunction; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting expression of c-FOS to reduce vascular endothelial cell injury is verified; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by reducing infiltration of macrophages is verified.

The invention provides lipid nanoparticles taking zinc phosphate as an inner core, a preparation method of the lipid nanoparticles and a medicine for treating aortic aneurysm, and relates to the technical field of biological medicines. The lipid nanoparticles provided by the invention comprise zinc phosphate nanoparticles, DOPA (Dioctyl-Phthalate Polyamide), ionizable cationic lipid, cholesterol and PEG (Polyethylene Glycol) lipid, the zinc phosphate nano-particles are inner cores of the lipid nano-particles. The lipid nanoparticles have excellent biocompatibility and safety and stable structure, and can improve the stability and delivery efficiency of nucleic acid (such as FBN1mRNA) as a carrier, thereby realizing effective treatment of diseases. According to the medicine for treating the aortic aneurysm, provided by the invention, accurate delivery of FBN1mRNA and expression in FBN1 cells can be realized, and angiogenesis and repair are promoted, so that accurate treatment of the aortic aneurysm is realized.

The invention discloses a morphological segmentation-based abdominal aortic aneurysm change monitoring method, which comprises the following steps of 1, performing three-dimensional modeling on an abdominal aortic aneurysm based on a clinical image; 2, determining the positions of the proximal end tumor neck and the telecentric end tumor neck of the aneurysm through a clinical image or a three-dimensional model, obtaining the midpoints of the proximal end tumor neck and the telecentric end tumor neck of the aneurysm, and extracting the vertical distance between the two midpoints as the vertical length (L) of the aneurysm; 3, based on the obtained vertical length L of the aneurysm, the abdominal aortic aneurysm is vertically and equally divided into n sections, and the length of each section is L / n; 4, obtaining the surface area and the volume of each section of the n sections, and obtaining various morphological parameters at different sections through calculation; and 5, quantitatively monitoring and evaluating the morphological change development of each section of the abdominal aortic aneurysm in combination with the result of the step 4.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible. The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (-)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

The invention relates to the technical field of animal model construction, and discloses a mouse abdominal aortic aneurysm model construction method. The construction method comprises the step that in a 18-month-old mouse, a sterile cotton piece soaked with elastinase is used for wrapping the kidney subabdominal aorta to induce formation of the abdominal aortic aneurysm. The mouse model can better reflect the degenerative change of the aortic wall of an elderly patient, better fits the clinical manifestation in the development speed and severity of aortic aneurysm, can more stably simulate the development process of the abdominal aortic aneurysm of the elderly patient, can be used as an effective tool for studying senescence-related aneurysm diseases, and has a wide application prospect. The method is helpful for revealing acceleration and aggravation processes of the elderly individuals in pathological development, and provides a more targeted theoretical basis and experimental support for designing and evaluating a new treatment method.

The present invention relates to an internal duct and fixing system (100) for branches for endovascular endoprostheses for endovascular treatment of aneurysms or dissections of the aorta, comprising (i) an endoprosthesis (200) provided with windows (210, 220, 230, 240), (ii) one or more occlusions (215, 225, 235, 245), fixed to the endoprosthesis (200) by means of suture (216, 226, 236, 246), reversibly occluding the windows (210, 220, 230, 240), and a set of fixing and duct elements (300) that forms one or more internal channels of the endoprosthesis (200), preferably in the region adjacent to one of the windows (210, 220, 230, 240). The present invention also relates to a corresponding endoprosthesis (200).

The invention discloses a pharmaceutical application of difatinib in treatment of aortic aneurysm, and relates to the field of cardiovascular systems. In an aortic aneurysm mouse model, after the difatinib is injected into the stomach, pathological dilatation of the aorta can be improved, and the death rate and the occurrence rate of the aortic aneurysm can be reduced. According to the invention, a new application field of the difatinib is developed, a new prevention and treatment method for the aortic aneurysm is provided, and a new way is provided for development of a novel medicine for the aortic aneurysm.

The invention belongs to the technical field of biology, and particularly relates to application of a medicine for inhibiting eEF2 in aortic dissection and aneurysm medicine and application of NFATc3 serving as an aortic dissection and aneurysm medicine target. The invention provides an application of NFATc3 as an aortic dissection and aneurysm drug target. The relationship between the NFATc3 and the aortic dissection and the aneurysm is found for the first time, specifically, the expression of the NFATc3 in the VSMCs of the human aortic aneurysm is obviously up-regulated, and the expression of the NFATc3 of cytoplasm and cell nucleus is obviously increased in human and mouse AAD tissues. Based on the discovery, the invention provides a new application of a targeted NFATc3 drug in preparation of drugs for preventing or / and treating aortic dissection and aneurysm. Experiments show that the development of aortic dissection and aneurysm can be significantly slowed down by inhibiting the expression or function of NFATc3.

The invention discloses an aortic aneurysm or aortic dissection filling piece and component, the filling piece is made of polyurethane shape memory foam, the expansion rate of the polyurethane shape memory foam is larger than 100 times, and a preparation method of the polyurethane shape memory foam comprises the steps that 1, the filling piece is made of polyurethane shape memory foam, and the expansion rate of the polyurethane shape memory foam is larger than 100 times; the preparation method comprises the following steps: preparing a polyurethane acrylate prepolymer from macromolecular polyol, diisocyanate, a chain extender containing disulfide bonds, other micromolecular chain extenders and an acrylate end-capping reagent; and 2, uniformly mixing the polyurethane acrylate prepolymer, a foaming agent, a foaming promoter, a photoinitiator and a high-boiling-point solvent to obtain a foaming solution, and sequentially carrying out light curing and foaming on the foaming solution to obtain the polyurethane shape memory foam. The filling piece is made of polyurethane shape memory foam and fully expands to form thrombus to fill a tumor cavity, and meanwhile, the filling piece is made of degradable materials and can be subsequently absorbed by the tumor cavity, so that foreign matter is prevented from being left in the body for a long time.

The present invention relates to an internal duct and fixing system (100) for branches for endovascular endoprostheses for endovascular treatment of aneurysms or dissections of the aorta, comprising (i) an endoprosthesis (200) provided with windows (210, 220, 230, 240), (ii) one or more occlusions (215, 225, 235, 245), fixed to the endoprosthesis (200) by means of suture (216, 226, 236, 246), reversibly occluding the windows (210, 220, 230, 240), and a set of fixing and duct elements (300) that forms one or more internal channels of the endoprosthesis (200), preferably in the region adjacent to one of the windows (210, 220, 230, 240). The present invention also relates to a corresponding endoprosthesis (200).

An axially compressible bare stent for an aorta, formed by interleaving at least two wires having different diameters, i.e., a first wire and a second wire, in an overlapping manner. In a natural release state, the bare stent has a metal coverage of at least 30%. The first wire has a diameter of 20-150 μm, and the second wire has a diameter of 150-600 μm. During the use in the treatment of aortic aneurysms and / or aortic dissection lesions, low liquid permeability and a strong radial support force are provided at a desired location in an aorta by means of the axial compressibility of the bare stent.

The present invention relates to the field of diagnosis and treatment of vascular diseases, and specifically to a marker for aortic aneurysm and a kit for auxiliary diagnosis of aortic aneurysm. Compared with a healthy control group, the miR663a content in the serum of patients with aortic aneurysm is significantly increased. And there is a correlation between miR663a and the time of onset. The shorter the onset time, the higher the miR663a content. Therefore, miR663a can be used as an aortic aneurysm marker for auxiliary diagnosis of aortic aneurysm. The kit for auxiliary diagnosis of aortic aneurysm described in the present invention can be used for clinical auxiliary diagnosis of aortic aneurysm quickly, sensitively and specifically, laying a foundation for clinicians to quickly and accurately grasp the patient's condition and evaluate the treatment effect.

Various concepts relate to Iliac branch endoprostheses extending for a length between a proximal end and a distal end, the iliac bifurcated endoprosthesis bifurcated from a primary flow channel into two flow channels. Various concepts relate to methods of deploying an endoprosthesis system to treat an aortic aneurysm including deploying an iliac bifurcated endoprosthesis into an ipsilateral leg of a bifurcated main body endoprosthesis, or a contralateral gate of a bifurcated main body endoprosthesis.

The invention discloses application of KAT7 as a target spot in treatment of aortic aneurysm and dissection. According to the application, an AngII-induced aortic aneurysm mouse model is applied, the treatment effect of the KAT7 inhibitor WM3835 on aortic aneurysm / dissection is detected through mouse survival rate, aortic aneurysm occurrence rate, aorta width, blood vessel staining and WB staining indexes, and the WM3835 can slow down the occurrence and progress of aortic aneurysm, reduce the occurrence of aortic dissection and improve the survival rate of aortic aneurysm / dissection, so that the KAT7 inhibitor WM3835 can be used for treating aortic aneurysm / dissection. And a new target and a new medicine are provided for clinically treating aorta and dissection of aortic aneurysm. The KAT7 inhibitor WM3835 provided by the invention is a brand new drug treatment means for treating aortic aneurysm and dissection, is an important supplement for operative treatment of aortic aneurysm / dissection, and has important clinical significance.

The invention provides application of a lactic dehydrogenase inhibitor in preparation of a medicine for preventing and / or treating aneurysm. The lactic dehydrogenase inhibitor is selected from a compound shown as a formula I in the specification or pharmaceutically acceptable salt thereof. Experiments show that the lactic dehydrogenase inhibitor can specifically inhibit synthesis of lactic acid in thoracic aortic aneurysm, recover expression of systolic genes, significantly inhibit vascular inflammation, maintain the systolic state of vascular smooth muscle cells and delay progress of thoracic aortic aneurysm. In addition, the lactic dehydrogenase inhibitor can also show a remarkable effect of inhibiting vasodilatation in thoracic aortic aneurysm mice, and has no remarkable influence on normal C57BL / 6J mice, so that the lactic dehydrogenase inhibitor is proved to have targeting and specific effects on thoracic aortic aneurysm. The lactic dehydrogenase inhibitor can also significantly inhibit vascular wall inflammatory response and elastic fiber destruction and delay the progress of thoracic aortic aneurysm by recovering the steady state function of vascular smooth muscle cells.

The present invention discloses a covered stent suitable for thoracic aortic aneurysm and thoracic aortic dissecting aneurysm, comprising a main stent and at least one group of movable stents, the main stent comprising a first cylindrical portion and a second cylindrical portion, a vertical partition is arranged in the first cylindrical portion, the vertical partition divides the first cylindrical portion into a first diversion cavity and a second diversion cavity, the cross-sectional area of ​​the first diversion cavity is larger than the cross-sectional area of ​​the second diversion cavity, the second cylindrical portion is integrally formed with the first cylindrical portion and communicated with the first diversion cavity, the movable stent comprises a connecting portion and a diversion portion, the connecting portion and the diversion portion are integrally formed, the connecting portion is arranged in the second diversion cavity, and is tightly fitted with the inner wall of the second diversion cavity. The stent can effectively solve the problem that the existing chimney stents are not tightly fitted between each other and between the chimney stent and the aorta, which is easy to cause blood leakage.

Various concepts involve an iliac bifurcation prosthesis extending a length between the proximal and distal ends, which bifurcates from the main flow channel into two flow channels. Various concepts also involve methods for deploying an in-situ prosthesis system to treat aortic aneurysms, including deploying the iliac bifurcation prosthesis into the ipsilateral leg of the bifurcation main prosthesis or into the contralateral opening of the bifurcation main prosthesis.

The invention relates to the field of animal models, in particular to sgRNA for preparing an aortic aneurysm animal model and a preparation method, and the sgRNA is characterized in that a TB structural domain of an exon 57 part of an FBN1 gene is knocked out on Bama miniature pig cells through a CRISPR / Cas9 gene editing method. The important structural domain of the FBN1 gene and the TB structural domain of the exon 57 part are screened out by deeply analyzing the structure and the function of the FBN1 gene and combining bioinformatics prediction and disease model related research. The prepared Bama miniature pig subjected to specific gene editing is expected to show unique value in medical research, disease model construction or specific animal husbandry production application, and powerful support is provided for research and development of related fields.

The invention belongs to the technical field of biological medicines, and particularly provides application of prasugrel or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating aortic aneurysm. The prasugrel or the pharmaceutically acceptable salt thereof is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

The present invention discloses a kit for predicting the growth and rupture risk of aortic aneurysms based on protein lactylation levels. The present invention constructs an aortic aneurysm and dissection mouse model, detects the protein lactylation level in its vascular tissue, and divides it into a high lactate level group and a low lactate level group. It is found that the formation of aortic aneurysms and the occurrence of aortic dissection are reduced in mice with low lactate levels. Further survival analysis shows that the survival curves between the two groups are significantly different. Therefore, on the basis of aortic aneurysm detection indicators, with protein lactylation level as the entry point, by identifying protein lactylation level, the protein lactylation level is associated with the growth and rupture risk of aortic aneurysms, thereby achieving the purpose of early prediction of aortic aneurysm deterioration and dissection occurrence, which is helpful for the prediction and early diagnosis and treatment of clinical critical events, and reduces the occurrence of serious adverse events such as dissection.

A stent graft for surgical delivery in a target site of a patient to treat an aortic aneurysm. The stent graft includes a graft formed of graft material including a first portion to be received by a lower portion of an aorta that is relatively straight, and a second portion to be received by an upper portion of an aorta that is curved. The stent graft includes a stent attached to the graft including stent members. In a first orientation, the first and second portions of the graft material are folded between the stent members over first and second adjacent portions of the graft to form a first pleat and a second pleat. In a second orientation, the second pleat has a graft space between corresponding stent members on a greater curvature side of the stent graft that is greater than on a lesser curvature side of the stent graft.

The present invention relates to a novel method for preventing or treating an aneurysm by using an IGF1R inhibitor and use. The present invention also relates to a formulation comprising IGF1C suitable for the method and use. The present invention further relates to a local minimally invasive delivery technique of drugs for preventing or treating an aneurysm, and in particular, to a local minimally invasive delivery technique for delivering a medicament comprising an IGF1R inhibitor according to the present invention.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

The invention discloses a segmented evaluation method for morphological change development of abdominal aortic aneurysm, which comprises the following steps of: 1, performing three-dimensional modeling on the abdominal aortic aneurysm based on a clinical image; 2, determining the positions of the proximal end tumor neck and the telecentric end tumor neck of the aneurysm through a clinical image or a three-dimensional model, obtaining the midpoints of the proximal end tumor neck and the telecentric end tumor neck of the aneurysm, and extracting the vertical distance between the two midpoints as the vertical length (L) of the aneurysm; 3, on the basis of the obtained vertical length L of the aneurysm, obtaining n-1 sections (Slice) which equally divide the abdominal aortic aneurysm into n sections, and the length of each section is L / n; 4, obtaining various morphological parameters at different sections; and 5, quantitatively monitoring and evaluating the morphological change development of each section of the abdominal aortic aneurysm in combination with the result of the step 4.